Research programme: small molecule enzyme inhibitors - OncoTherapy Science

Drug Profile

Research programme: small molecule enzyme inhibitors - OncoTherapy Science

Alternative Names: Methyltransferase SUV39H2 inhibitors - OncoTherapy Science; OTS-514; OTS-964; T-LAK cell-originated protein kinase inhibitors - OncoTherapy Science; TOPK inhibitors - OncoTherapy Science

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; University of Chicago
  • Class Small molecules
  • Mechanism of Action Methyltransferase inhibitors; PDZ-binding kinase inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer

Most Recent Events

  • 29 Feb 2016 Pharmacodynamics data from a preclinical trial in Renal cancer released by OncoTherapy Science
  • 28 Dec 2015 OncoTherapy Science has patent protection for TOPK-specific inhibitors in Japan
  • 06 Mar 2015 OncoTherapy Science has patent protection for TOPK inhibitors in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top